A person with a two hour history of phlegmasia cerulea dolens (left leg, right side of image)
Phlegmasia cerulea dolens (PCD) (literally: 'painful blue inflammation'), not to be confused with precedingphlegmasia alba dolens, is an uncommon severe form of lower extremitydeep venous thrombosis (DVT) that obstructs blood outflow from a vein. Upper extremity PCD is less common, occurring in under 10% of all cases.[1] PCD results from extensivethrombotic occlusion (blockage by athrombus) of extremity veins, most commonly aniliofemoral DVT, of theiliac vein and/orcommon femoral vein.[2][3] It is a medical emergency requiring immediate evaluation and treatment.
It is characterized by progressive lower extremity edema distal to the thigh, tight shiny skin,cyanosis (inadequate blood oxygenation),petechiae orpurpura, and sudden severe pain of the affected limb in proportion to the level of venous blockage. Patients often have difficulty walking.Blisters, bullae,paresthesias, and motor weakness may develop in severe cases, along with gangrene in ~50% of cases.[4][5] Distal pulses are palpable early on but may diminish over time, anddoppler signal can be usually heard throughout disease progression.[6] The left limb is more commonly affected due to its vascular anatomy (the rightinternal iliac artery directly overlies the left iliac vein).[7][8]
When athrombus occludes an extremityvein, pressure backs up in the venous system leading plasma fluid to leak out into theinterstitium of the affected limb. This increases the pressure of that limb compartment, which can collapse the arteries and lead to acuteischemia,gangrene,hypovolemia, and hemodynamic instability.[14][15]
PCD is best diagnosed with contrast venography, butvenous duplex ultrasonography is used more commonly in clinical practice. Magnetic resonance and computed tomographyvenography can also be used.[16]
PCD is fully reversible if the causalvenous thrombus is promptly removed.[23] In the 40-60% of people who go on to develop venous gangrene, there is a 20-50% risk of amputation and 20-40% mortality rate.[24][25] Following PCD resolution patients are more likely to develop venous insufficiency andpost-thrombotic syndrome[26]
PCD is most likely to occur in people in their 50s and 60s, but can occur as early as 6 months old. There is slight male predominance of around 1.5:1.[29][30]
This phenomenon was first discovered by Fabricus Hildanius in the16th century, and was officially termed "phlegmasia cerulea dolens" by Gregoire in 1938.[31][32]Phlegmasia originates from theGreek rootphlegma (inflammation),cerulea originates fromLatin rootcaeruleus (dark blue), anddolens originates from Latin worddolens (suffering).[33]
^Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9th ed.). Philadelphia, PA. 2019.ISBN978-0-323-58130-1.OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
^Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9th ed.). Philadelphia, PA. 2019.ISBN978-0-323-58130-1.OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
^Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9th ed.). Philadelphia, PA. 2019.ISBN978-0-323-58130-1.OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
^Chang, Grace; Yeh, James J. (July 2014). "Fulminant phlegmasia cerulea dolens with concurrent cholangiocarcinoma and a lupus anticoagulant: a case report and review of the literature".Blood Coagulation & Fibrinolysis.25 (5):507–511.doi:10.1097/MBC.0000000000000057.ISSN1473-5733.PMID24553060.S2CID10642849.
^Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9th ed.). Philadelphia, PA. 2019.ISBN978-0-323-58130-1.OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
^Chang, Grace; Yeh, James J. (July 2014). "Fulminant phlegmasia cerulea dolens with concurrent cholangiocarcinoma and a lupus anticoagulant: a case report and review of the literature".Blood Coagulation & Fibrinolysis.25 (5):507–511.doi:10.1097/MBC.0000000000000057.ISSN1473-5733.PMID24553060.S2CID10642849.
^Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9th ed.). Philadelphia, PA. 2019.ISBN978-0-323-58130-1.OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
^Chang, Grace; Yeh, James J. (July 2014). "Fulminant phlegmasia cerulea dolens with concurrent cholangiocarcinoma and a lupus anticoagulant: a case report and review of the literature".Blood Coagulation & Fibrinolysis.25 (5):507–511.doi:10.1097/MBC.0000000000000057.ISSN1473-5733.PMID24553060.S2CID10642849.
^Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9th ed.). Philadelphia, PA. 2019.ISBN978-0-323-58130-1.OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)